Britain and America have established a important commercial pact that will keep no duties on UK drug exports being sold in the US market.
The Terms of the Deal
In exchange for the tariff guarantee, the UK has agreed to increase spending on pharmaceuticals through the NHS. This move guarantees that duties on these crucial goods will stay at zero for a duration of the next three years.
This development is in response to earlier warnings to hike import taxes on branded drug products, with potential rates discussed as high as double the cost.
"This arrangement between the Britain reinforces the worldwide climate for cutting-edge drugs and introduces much-needed balance to transatlantic medicine commerce," a release said.
Economic Impact
Medicines are one of the UK's biggest exports to the United States, which is by far the primary buyer for large British pharmaceutical firms.
Trade data indicate that in the year to the end of September, the UK exported drugs valued at billions to the US. This figure made up nearly one-fifth of British export trade in that period.
"This deal secures work, boosts investment and sets the stage for the UK to emerge as a international leader for medical research," the Business and Trade Secretary remarked.
Detailed NHS Changes
The deal includes several specific pledges from the British government:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it considers new treatments to be unaffordable by 25%.
- Increased NHS Spending: There is a goal to increase total health service expenditure on treatments from 0.3% of the national economy to 0.6% over the next decade.
- Rebate Cap: The percentage drug companies must pay back to the NHS to prevent overspending will be limited at fifteen percent. Previously, repayments were more than 20%.
Recent Tensions
The pact comes amid a protracted tension between the sector and the UK government over medicine costs and NHS adoption.
These tensions were exacerbated by arguments that American patients were paying several times more for the same drugs than consumers in the UK and Europe.
Over the last 18 months, several major pharmaceutical investments in the UK have been delayed or scrapped, while major expansions have been pledged toward US facilities.
One official publicly accepted that the NHS had to spend more on medicines, noting that its expenditure on drugs had decreased as a percentage of its overall budget over the last ten years.
